1nme › Citations

In situ assembly of enzyme inhibitors using extended tethering.

Erlanson DA, Lam JW, Wiesmann C, Luong TN, Simmons RL, DeLano WL, Choong IC, Burdett MT, Flanagan WM, Lee D, Gordon EM, O'Brien T
Nat Biotechnol 21 308-14 (2003)
Related entries: 1nmq, 1nms

Cited: 105 times
EuropePMC logo PMID: 12563278

Abstract

Cysteine aspartyl protease-3 (caspase-3) is a mediator of apoptosis and a therapeutic target for a wide range of diseases. Using a dynamic combinatorial technology, 'extended tethering', we identified unique nonpeptidic inhibitors for this enzyme. Extended tethering allowed the identification of ligands that bind to discrete regions of caspase-3 and also helped direct the assembly of these ligands into small-molecule inhibitors. We first designed a small-molecule 'extender' that irreversibly alkylates the cysteine residue of caspase-3 and also contains a thiol group. The modified protein was then screened against a library of disulfide-containing small-molecule fragments. Mass-spectrometry was used to identify ligands that bind noncovalently to the protein and that also form a disulfide linkage with the extender. Linking the selected fragments with binding elements from the extenders generates reversible, tight-binding molecules that are druglike and distinct from known inhibitors. One molecule derived from this approach inhibited apoptosis in cells.

Reviews - 1nme mentioned but not cited (2)

  1. The protein structures that shape caspase activity, specificity, activation and inhibition. Fuentes-Prior P, Salvesen GS. Biochem J 384 201-232 (2004)
  2. Small Molecule Active Site Directed Tools for Studying Human Caspases. Poreba M, Szalek A, Kasperkiewicz P, Rut W, Salvesen GS, Drag M. Chem Rev 115 12546-12629 (2015)

Articles - 1nme mentioned but not cited (24)

  1. Discovery of an allosteric site in the caspases. Hardy JA, Lam J, Nguyen JT, O'Brien T, Wells JA. Proc Natl Acad Sci U S A 101 12461-12466 (2004)
  2. Thioredoxin is required for S-nitrosation of procaspase-3 and the inhibition of apoptosis in Jurkat cells. Mitchell DA, Morton SU, Fernhoff NB, Marletta MA. Proc Natl Acad Sci U S A 104 11609-11614 (2007)
  3. Stretching to understand proteins - a survey of the protein data bank. Sułkowska JI, Cieplak M. Biophys J 94 6-13 (2008)
  4. Tunable allosteric library of caspase-3 identifies coupling between conserved water molecules and conformational selection. Maciag JJ, Mackenzie SH, Tucker MB, Schipper JL, Swartz P, Clark AC. Proc Natl Acad Sci U S A 113 E6080-E6088 (2016)
  5. ProteMiner-SSM: a web server for efficient analysis of similar protein tertiary substructures. Chang DT, Chen CY, Chung WC, Oyang YJ, Juan HF, Huang HC. Nucleic Acids Res 32 W76-82 (2004)
  6. Computational protein design: validation and possible relevance as a tool for homology searching and fold recognition. Schmidt Am Busch M, Sedano A, Simonson T. PLoS One 5 e10410 (2010)
  7. In silico identification and crystal structure validation of caspase-3 inhibitors without a P1 aspartic acid moiety. Ganesan R, Jelakovic S, Mittl PR, Caflisch A, Grütter MG. Acta Crystallogr Sect F Struct Biol Cryst Commun 67 842-850 (2011)
  8. A new definition and properties of the similarity value between two protein structures. Saberi Fathi SM. J Biol Phys 42 621-636 (2016)
  9. Effect of monosodium glutamate on serum sex hormones and uterine histology in female rats along with its molecular docking and in-silico toxicity. Abdulghani MAM, Alshehade SA, Kamran S, Alshawsh MA. Heliyon 8 e10967 (2022)
  10. In Vitro Antiproliferative Apoptosis Induction and Cell Cycle Arrest Potential of Saudi Sidr Honey against Colorectal Cancer. Qanash H, Bazaid AS, Binsaleh NK, Patel M, Althomali OW, Sheeha BB. Nutrients 15 3448 (2023)
  11. Network Pharmacology and Molecular Docking Analysis on Pharmacological Mechanisms of Astragalus membranaceus in the Treatment of Gastric Ulcer. Zhou P, Zhou R, Min Y, An LP, Wang F, Du QY. Evid Based Complement Alternat Med 2022 9007396 (2022)
  12. Potential mechanisms underlying the therapeutic roles of sinisan formula in depression: Based on network pharmacology and molecular docking study. Wang H, Liu J, He J, Huang D, Xi Y, Xiao T, Ouyang Q, Zhang S, Wan S, Chen X. Front Psychiatry 13 1063489 (2022)
  13. Identification of Bioactive Components of Stephania epigaea Lo and Their Potential Therapeutic Targets by UPLC-MS/MS and Network Pharmacology. Li X, Li M, Mao Z, Du Y, Brown S, Min X, Zhang R, Zhong Y, Dong Y, Liu Z, Lin C. Evid Based Complement Alternat Med 2022 3641586 (2022)
  14. Identifying potential pharmacological targets and molecular pathways of Meliae cortex for COVID-19 therapy. Khan SA, Lee TKW. Front Immunol 14 1128164 (2023)
  15. Integrated Network Pharmacology, Molecular Docking, Molecular Simulation, and In Vitro Validation Revealed the Bioactive Components in Soy-Fermented Food Products and the Underlying Mechanistic Pathways in Lung Cancer. Elkhalifa AEO, Banu H, Khan MI, Ashraf SA. Nutrients 15 3949 (2023)
  16. Leaf Extract of Perilla frutescens (L.) Britt Promotes Adipocyte Browning via the p38 MAPK Pathway and PI3K-AKT Pathway. Chen F, Wu S, Li D, Dong J, Huang X. Nutrients 15 1487 (2023)
  17. Mechanism of Huaiqihuang in treatment of diabetic kidney disease based on network pharmacology, molecular docking and in vitro experiment. Wang J, Ma G, Zhang P, Ma C, Shao J, Wang L, Ma C. Medicine (Baltimore) 102 e36177 (2023)
  18. Molecular Mechanisms of Notopterygii rhizoma Et Radix for Treating Arrhythmia Based on Network Pharmacology. Wei P, Shang J, Liu H, Xing W, Tan Y. Comb Chem High Throughput Screen 26 1560-1570 (2023)
  19. Network Pharmacology and Experimental Validation to Explore That Celastrol Targeting PTEN is the Potential Mechanism of Tripterygium wilfordii (Lév.) Hutch Against IgA Nephropathy. Zhao J, Liu H, Xia M, Chen Q, Wan L, Leng B, Tang C, Chen G, Liu Y, Zhang L, Liu H. Drug Des Devel Ther 17 887-900 (2023)
  20. Network pharmacology and molecular docking-based prediction of active compounds and mechanisms of action of Cnidii Fructus in treating atopic dermatitis. Khan SA, Wu Y, Li AS, Fu XQ, Yu ZL. BMC Complement Med Ther 22 275 (2022)
  21. Network pharmacology prediction and experimental verification of Rhubarb-Peach Kernel promoting apoptosis in endometriosis. Liao Z, Lei Y, Peng L, Fu X, Wang W, Yang D. BMC Complement Med Ther 23 291 (2023)
  22. Optimization of tetrastigma hemsleyanum extraction process based on GA-BPNN model and analysis of its antioxidant effect. Shu J, Zhao Y, Zhou Y, Lin F, Song J, Li X. Heliyon 9 e20200 (2023)
  23. Synthesis and Discovery of Ligustrazine-Heterocycle Derivatives as Antitumor Agents. Ma S, Zhang N, Hou J, Liu S, Wang J, Lu B, Zhu F, Wei P, Hong G, Liu T. Front Chem 10 941367 (2022)
  24. Unveiling the Mechanistic Singularities of Caspases: A Computational Analysis of the Reaction Mechanism in Human Caspase-1. Ramos-Guzmán CA, Ruiz-Pernía JJ, Zinovjev K, Tuñón I. ACS Catal 13 4348-4361 (2023)


Reviews citing this publication (34)

  1. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Arkin MR, Wells JA. Nat Rev Drug Discov 3 301-317 (2004)
  2. Fragment-based lead discovery. Rees DC, Congreve M, Murray CW, Carr R. Nat Rev Drug Discov 3 660-672 (2004)
  3. Emerging principles in protease-based drug discovery. Drag M, Salvesen GS. Nat Rev Drug Discov 9 690-701 (2010)
  4. Tethering: fragment-based drug discovery. Erlanson DA, Wells JA, Braisted AC. Annu Rev Biophys Biomol Struct 33 199-223 (2004)
  5. Apoptosis-based therapies and drug targets. Fischer U, Schulze-Osthoff K. Cell Death Differ 12 Suppl 1 942-961 (2005)
  6. Fragment-based lead discovery: leads by design. Carr RA, Congreve M, Murray CW, Rees DC. Drug Discov Today 10 987-992 (2005)
  7. In situ click chemistry: probing the binding landscapes of biological molecules. Mamidyala SK, Finn MG. Chem Soc Rev 39 1252-1261 (2010)
  8. Theory of free energy and entropy in noncovalent binding. Zhou HX, Gilson MK. Chem Rev 109 4092-4107 (2009)
  9. Dynamic combinatorial/covalent chemistry: a tool to read, generate and modulate the bioactivity of compounds and compound mixtures. Herrmann A. Chem Soc Rev 43 1899-1933 (2014)
  10. Dynamic combinatorial chemistry: a tool to facilitate the identification of inhibitors for protein targets. Mondal M, Hirsch AK. Chem Soc Rev 44 2455-2488 (2015)
  11. Hit discovery and hit-to-lead approaches. Keseru GM, Makara GM. Drug Discov Today 11 741-748 (2006)
  12. Molecular dynamics in drug design. Zhao H, Caflisch A. Eur J Med Chem 91 4-14 (2015)
  13. Fragment-based lead discovery: a chemical update. Erlanson DA. Curr Opin Biotechnol 17 643-652 (2006)
  14. Systematic Targeting of Protein-Protein Interactions. Modell AE, Blosser SL, Arora PS. Trends Pharmacol Sci 37 702-713 (2016)
  15. Biophysical and computational fragment-based approaches to targeting protein-protein interactions: applications in structure-guided drug discovery. Winter A, Higueruelo AP, Marsh M, Sigurdardottir A, Pitt WR, Blundell TL. Q Rev Biophys 45 383-426 (2012)
  16. Apoptolidin: induction of apoptosis by a natural product. Daniel PT, Koert U, Schuppan J. Angew Chem Int Ed Engl 45 872-893 (2006)
  17. Caspases as therapeutic targets. Howley B, Fearnhead HO. J Cell Mol Med 12 1502-1516 (2008)
  18. Receptor-assisted combinatorial chemistry: thermodynamics and kinetics in drug discovery. Cheeseman JD, Corbett AD, Gleason JL, Kazlauskas RJ. Chemistry 11 1708-1716 (2005)
  19. Biochemical applications of mass spectrometry in pharmaceutical drug discovery. Geoghegan KF, Kelly MA. Mass Spectrom Rev 24 347-366 (2005)
  20. Fragonomics: fragment-based drug discovery. Zartler ER, Shapiro MJ. Curr Opin Chem Biol 9 366-370 (2005)
  21. Molecular targeting of angiogenesis. Alessi P, Ebbinghaus C, Neri D. Biochim Biophys Acta 1654 39-49 (2004)
  22. Ligand-based vascular targeting of disease. Rybak JN, Trachsel E, Scheuermann J, Neri D. ChemMedChem 2 22-40 (2007)
  23. Structure-based design of small-molecule protein-protein interaction modulators: the story so far. Falchi F, Caporuscio F, Recanatini M. Future Med Chem 6 343-357 (2014)
  24. Making drugs on proteins: site-directed ligand discovery for fragment-based lead assembly. Erlanson DA, Hansen SK. Curr Opin Chem Biol 8 399-406 (2004)
  25. Protein-Templated Fragment Ligations-From Molecular Recognition to Drug Discovery. Jaegle M, Wong EL, Tauber C, Nawrotzky E, Arkona C, Rademann J. Angew Chem Int Ed Engl 56 7358-7378 (2017)
  26. The ways and means of fragment-based drug design. Doak BC, Norton RS, Scanlon MJ. Pharmacol Ther 167 28-37 (2016)
  27. Dynamic template-assisted strategies in fragment-based drug discovery. Schmidt MF, Rademann J. Trends Biotechnol 27 512-521 (2009)
  28. Molecular targeting of angiogenesis for imaging and therapy. Brack SS, Dinkelborg LM, Neri D. Eur J Nucl Med Mol Imaging 31 1327-1341 (2004)
  29. New insights into the kinetic target-guided synthesis of protein ligands. Oueis E, Sabot C, Renard PY. Chem Commun (Camb) 51 12158-12169 (2015)
  30. Library screening by fragment-based docking. Huang D, Caflisch A. J Mol Recognit 23 183-193 (2010)
  31. The chemical hunt for the identification of drugable targets. Meisner NC, Hintersteiner M, Uhl V, Weidemann T, Schmied M, Gstach H, Auer M. Curr Opin Chem Biol 8 424-431 (2004)
  32. New approaches in identifying drugs to inactivate oncogene products. Liu R, Hsieh CY, Lam KS. Semin Cancer Biol 14 13-21 (2004)
  33. Tailored therapeutics based on 1,2,3-1H-triazoles: a mini review. Prasher P, Sharma M. Medchemcomm 10 1302-1328 (2019)
  34. Recent advances in DNA-encoded dynamic libraries. Shi B, Zhou Y, Li X. RSC Chem Biol 3 407-419 (2022)

Articles citing this publication (45)

  1. Encoded self-assembling chemical libraries. Melkko S, Scheuermann J, Dumelin CE, Neri D. Nat Biotechnol 22 568-574 (2004)
  2. p38-MAPK signals survival by phosphorylation of caspase-8 and caspase-3 in human neutrophils. Alvarado-Kristensson M, Melander F, Leandersson K, Rönnstrand L, Wernstedt C, Andersson T. J Exp Med 199 449-458 (2004)
  3. In situ click chemistry: enzyme-generated inhibitors of carbonic anhydrase II. Mocharla VP, Colasson B, Lee LV, Röper S, Sharpless KB, Wong CH, Kolb HC. Angew Chem Int Ed Engl 44 116-120 (2004)
  4. Using a fragment-based approach to target protein-protein interactions. Scott DE, Ehebauer MT, Pukala T, Marsh M, Blundell TL, Venkitaraman AR, Abell C, Hyvönen M. Chembiochem 14 332-342 (2013)
  5. Reversible, allosteric small-molecule inhibitors of regulator of G protein signaling proteins. Blazer LL, Roman DL, Chung A, Larsen MJ, Greedy BM, Husbands SM, Neubig RR. Mol Pharmacol 78 524-533 (2010)
  6. Fragment-based screening using surface plasmon resonance technology. Perspicace S, Banner D, Benz J, Müller F, Schlatter D, Huber W. J Biomol Screen 14 337-349 (2009)
  7. Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors. Ji H, Stanton BZ, Igarashi J, Li H, Martásek P, Roman LJ, Poulos TL, Silverman RB. J Am Chem Soc 130 3900-3914 (2008)
  8. In situ click chemistry: a powerful means for lead discovery. Sharpless KB, Manetsch R. Expert Opin Drug Discov 1 525-538 (2006)
  9. Role of loop bundle hydrogen bonds in the maturation and activity of (Pro)caspase-3. Feeney B, Pop C, Swartz P, Mattos C, Clark AC. Biochemistry 45 13249-13263 (2006)
  10. Dynamic diselenide bonds: exchange reaction induced by visible light without catalysis. Ji S, Cao W, Yu Y, Xu H. Angew Chem Int Ed Engl 53 6781-6785 (2014)
  11. Unusual arginine formations in protein function and assembly: rings, strings, and stacks. Neves MA, Yeager M, Abagyan R. J Phys Chem B 116 7006-7013 (2012)
  12. Structural and kinetic analysis of caspase-3 reveals role for s5 binding site in substrate recognition. Fang B, Boross PI, Tozser J, Weber IT. J Mol Biol 360 654-666 (2006)
  13. In vivo protein biotinylation and sample preparation for the proteomic identification of organ- and disease-specific antigens accessible from the vasculature. Roesli C, Neri D, Rybak JN. Nat Protoc 1 192-199 (2006)
  14. On-Demand Targeting: Investigating Biology with Proximity-Directed Chemistry. Long MJ, Poganik JR, Aye Y. J Am Chem Soc 138 3610-3622 (2016)
  15. Extended substrate recognition in caspase-3 revealed by high resolution X-ray structure analysis. Ganesan R, Mittl PR, Jelakovic S, Grütter MG. J Mol Biol 359 1378-1388 (2006)
  16. Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery. Erlanson DA, Arndt JW, Cancilla MT, Cao K, Elling RA, English N, Friedman J, Hansen SK, Hession C, Joseph I, Kumaravel G, Lee WC, Lind KE, McDowell RS, Miatkowski K, Nguyen C, Nguyen TB, Park S, Pathan N, Penny DM, Romanowski MJ, Scott D, Silvian L, Simmons RL, Tangonan BT, Yang W, Sun L. Bioorg Med Chem Lett 21 3078-3083 (2011)
  17. Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry. Cancilla MT, He MM, Viswanathan N, Simmons RL, Taylor M, Fung AD, Cao K, Erlanson DA. Bioorg Med Chem Lett 18 3978-3981 (2008)
  18. A fragment-based approach to probing adenosine recognition sites by using dynamic combinatorial chemistry. Scott DE, Dawes GJ, Ando M, Abell C, Ciulli A. Chembiochem 10 2772-2779 (2009)
  19. Metalloporphyrins inactivate caspase-3 and -8. Blumenthal SB, Kiemer AK, Tiegs G, Seyfried S, Höltje M, Brandt B, Höltje HD, Zahler S, Vollmar AM. FASEB J 19 1272-1279 (2005)
  20. Kinetic template-guided tethering of fragments. Nonoo RH, Armstrong A, Mann DJ. ChemMedChem 7 2082-2086 (2012)
  21. Covalent capture: merging covalent and noncovalent synthesis. Prins LJ, Scrimin P. Angew Chem Int Ed Engl 48 2288-2306 (2009)
  22. Isolation of a small-molecule inhibitor of the antiapoptotic protein Bcl-xL from a DNA-encoded chemical library. Melkko S, Mannocci L, Dumelin CE, Villa A, Sommavilla R, Zhang Y, Grütter MG, Keller N, Jermutus L, Jackson RH, Scheuermann J, Neri D. ChemMedChem 5 584-590 (2010)
  23. Selective identification of cooperatively binding fragments in a high-throughput ligation assay enables development of a picomolar caspase-3 inhibitor. Schmidt MF, El-Dahshan A, Keller S, Rademann J. Angew Chem Int Ed Engl 48 6346-6349 (2009)
  24. Custom chemical microarray production and affinity fingerprinting for the S1 pocket of factor VIIa. Dickopf S, Frank M, Junker HD, Maier S, Metz G, Ottleben H, Rau H, Schellhaas N, Schmidt K, Sekul R, Vanier C, Vetter D, Czech J, Lorenz M, Matter H, Schudok M, Schreuder H, Will DW, Nestler HP. Anal Biochem 335 50-57 (2004)
  25. Structural model of the p14/SF3b155 · branch duplex complex. Schellenberg MJ, Dul EL, MacMillan AM. RNA 17 155-165 (2011)
  26. Identification of potent and novel small-molecule inhibitors of caspase-3. Allen DA, Pham P, Choong IC, Fahr B, Burdett MT, Lew W, DeLano WL, Gordon EM, Lam JW, O'Brien T, Lee D. Bioorg Med Chem Lett 13 3651-3655 (2003)
  27. Malonate-assisted purification of human caspases. Scheer JM, Wells JA, Romanowski MJ. Protein Expr Purif 41 148-153 (2005)
  28. Letter Identification of specific tethered inhibitors for caspase-5. Gao J, Wells JA. Chem Biol Drug Des 79 209-215 (2012)
  29. A novel protocol to accelerate dynamic combinatorial chemistry via isolation of ligand-target adducts from dynamic combinatorial libraries: a case study identifying competitive inhibitors of lysozyme. Fang Z, He W, Li X, Li Z, Chen B, Ouyang P, Guo K. Bioorg Med Chem Lett 23 5174-5177 (2013)
  30. Activation Mechanism of the Bacteroides fragilis Cysteine Peptidase, Fragipain. Herrou J, Choi VM, Bubeck Wardenburg J, Crosson S. Biochemistry 55 4077-4084 (2016)
  31. Identification of inhibitors targeting Mycobacterium tuberculosis cell wall biosynthesis via dynamic combinatorial chemistry. Fu J, Fu H, Dieu M, Halloum I, Kremer L, Xia Y, Pan W, Vincent SP. Chem Commun (Camb) 53 10632-10635 (2017)
  32. "Click" synthesis of small-molecule inhibitors targeting caspases. Ng SL, Yang PY, Chen KY, Srinivasan R, Yao SQ. Org Biomol Chem 6 844-847 (2008)
  33. Solid phase synthesis of selective caspase-3 peptide inhibitors. Grimm EL, Roy B, Aspiotis R, Bayly CI, Nicholson DW, Rasper DM, Renaud J, Roy S, Tam J, Tawa P, Vaillancourt JP, Xanthoudakis S, Zamboni RJ. Bioorg Med Chem 12 845-851 (2004)
  34. Auto In Silico Ligand Directing Evolution to Facilitate the Rapid and Efficient Discovery of Drug Lead. Wu F, Zhuo L, Wang F, Huang W, Hao G, Yang G. iScience 23 101179 (2020)
  35. Covalent labelling of fusion proteins in live cells via an engineered receptor-ligand pair. Krusemark CJ, Belshaw PJ. Org Biomol Chem 5 2201-2204 (2007)
  36. Structural analysis of caspase-1 inhibitors derived from Tethering. O'Brien T, Fahr BT, Sopko MM, Lam JW, Waal ND, Raimundo BC, Purkey HE, Pham P, Romanowski MJ. Acta Crystallogr Sect F Struct Biol Cryst Commun 61 451-458 (2005)
  37. Proteintemplat-gesteuerte Fragmentligationen - von der molekularen Erkennung zur Wirkstofffindung. Jaegle M, Wong EL, Tauber C, Nawrotzky E, Arkona C, Rademann J. Angew Chem Weinheim Bergstr Ger 129 7464-7485 (2017)
  38. 2'-O-Appended polyamines that increase triple-helix-forming oligonucleotide affinity are selected by dynamic combinatorial chemistry. Azéma L, Bathany K, Rayner B. Chembiochem 11 2513-2516 (2010)
  39. Module assembly for protein-surface recognition: geranylgeranyltransferase I bivalent inhibitors for simultaneous targeting of interior and exterior protein surfaces. Machida S, Usuba K, Blaskovich MA, Yano A, Harada K, Sebti SM, Kato N, Ohkanda J. Chemistry 14 1392-1401 (2008)
  40. Salicylates are interference compounds in TR-FRET assays. Hanley RP, Horvath S, An J, Hof F, Wulff JE. Bioorg Med Chem Lett 26 973-977 (2016)
  41. Selective extraction of G-quadruplex ligands from a rationally designed scaffold-based dynamic combinatorial library. Nielsen MC, Ulven T. Chemistry 14 9487-9490 (2008)
  42. Use of "tethering" for the identification of a small molecule that binds to a dynamic hot spot on the interleukin-2 surface. Berg T. Chembiochem 5 1051-1053 (2004)
  43. Towards identification of protein-protein interaction stabilizers via inhibitory peptide-fragment hybrids using templated fragment ligation. Srdanović S, Hegedüs Z, Warriner SL, Wilson AJ. RSC Chem Biol 3 546-550 (2022)
  44. Peptides from human BNIP5 and PXT1 and non-native binders of pro-apoptotic BAK can directly activate or inhibit BAK-mediated membrane permeabilization. Aguilar F, Yu S, Grant RA, Swanson S, Ghose D, Su BG, Sarosiek KA, Keating AE. Structure 31 265-281.e7 (2023)
  45. The potential use of glycosyl-transferase inhibitors for targeted reduction of S. mutans biofilms in dental materials. Scaffa PMC, Kendall A, Icimoto MY, Fugolin APP, Logan MG, DeVito-Moraes AG, Lewis SH, Zhang H, Wu H, Pfeifer CS. Sci Rep 13 11889 (2023)


Related citations provided by authors (1)

  1. Identification of Potent and Selective Small-Molecule Inhibitors of Caspase-3 through the Use of Extended Tethering and Structure-Based Drug Design. Choong IC, Lew W, Lee D, Pham P, Burdett MT, Lam JW, Wiesmann C, Luong TN, Fahr B, O'Brian T J. Med. Chem. 45 5005-5022 (2002)

Quick links